Key result
New-onset AF in COVID-19 pneumonia is linked to ~10-fold higher troponin I, reflecting acute myocardial injury.
Why the study?
Given the high lethality of COVID-19 and rising AF prevalence linked to the pandemic, the study investigated the predictors of new-onset AF and the characteristics of acute myocardial injury in patients with COVID-19 pneumonia.
Cohort (n=100)
No
Absolute Event Rate: 289.6% vs 29.4%
p-value: p=0.0027
COVID-19 pneumonia is associated with acute myocardial injury, systemic inflammation, and hypercoagulation, which may induce new-onset atrial fibrillation, particularly in patients with reduced ejection fraction and cardiomegaly.
May flag myocardial injury in COVID-19 AF; hypothesis-generating, leaves monitoring or therapy changes open.
No takes yet. Share an insight, caveat, or question.
Makeeva et al. (2023) conducted a cohort in COVID-19 pneumonia (n=100). New-onset atrial fibrillation vs. No atrial fibrillation was evaluated on Troponin I level (ng/L) (p=0.0027). New-onset atrial fibrillation in patients with COVID-19 pneumonia was associated with significantly higher troponin I levels (289.6 vs 29.4 ng/L), reflecting acute myocardial injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: